Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Wungki Park"'
Autor:
Dae Won Kim, Young-chul Kim, Bence P. Kovari, Vincent Chung, Olatunji B. Alese, Bassel F. El-Rayes, Daneng Li, Wungki Park, Richard D. Kim
Publikováno v:
European Journal of Cancer. 176:171-180
Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients with refractory biliary tract cancer, suggesting the significant clinical benefit of nivolumab in selected patients and the necessity of
Autor:
Vinod P. Balachandran, Wungki Park, Jeffrey A. Drebin, Kenneth Seier, Alice C. Wei, Kenneth H. Yu, Jared Bassmann, Kevin C. Soares, William R. Jarnagin, Christopher H. Crane, Mithat Gonen, Marsha Reyngold, T. Peter Kingham, Joshua S. Jolissaint, Michael I. D’Angelica, Eileen M. O'Reilly, Anna M. Varghese
Publikováno v:
Hepatobiliary Surg Nutr
OBJECTIVE We sought to compare overall survival (OS) and disease control for patients with localized pancreatic ductal adenocarcinoma (PDAC) treated with ablative dose radiotherapy (A-RT) versus resection. SUMMARY BACKGROUND DATA Locoregional treatme
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Autor:
Binbin Zheng-Lin, Michael Rainone, Anna M. Varghese, Kenneth H. Yu, Wungki Park, Michael Berger, Miika Mehine, Joanne Chou, Marinela Capanu, Diana Mandelker, Zsofia K. Stadler, Ozge Birsoy, Sowmya Jairam, Ciyu Yang, Yirong Li, Donna Wong, Jamal K Benhamida, Marc Ladanyi, Liying Zhang, Eileen M. O’Reilly
Publikováno v:
Molecular diagnosistherapy. 26(6)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5-6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There
Publikováno v:
JCO Precision Oncology.
Autor:
Wungki Park, Catherine A. O'Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F. Chou, Shigeaki Umeda, Marsha Reyngold, Anna M. Varghese, Fergus Keane, Fiyinfolu Balogun, Kenneth H. Yu, David P. Kelsen, Christopher Crane, Marinela Capanu, Christine Iacobuzio-Donahue, Eileen M. O'Reilly
Publikováno v:
Clin Cancer Res
Purpose: Characterizing germline and somatic ATM variants (gATMm, sATMm) zygosity and their contribution to homologous recombination deficiency (HRD) is important for therapeutic strategy in pancreatic ductal adenocarcinoma (PDAC). Experimental Desig
Autor:
Kenneth H. Yu, Jennifer Park, Avni Mittal, Ghassan K. Abou‐Alfa, Imane El Dika, Andrew S. Epstein, David H. Ilson, David P. Kelsen, Geoffrey Y. Ku, Jia Li, Wungki Park, Anna M. Varghese, Joanne F‐L Chou, Marinela Capanu, Brandon Cooper, Andrew Bartlett, Devan McCarthy, Vineet Sangar, Brian McCarthy, Eileen M. O'Reilly
Publikováno v:
CancerREFERENCES. 128(15)
Pancreatic adenocarcinoma (PDAC) remains a refractory disease; however, modern cytotoxic chemotherapeutics can induce tumor regression and extend life. A blood-based, pharmacogenomic, chemosensitivity assay using gene expression profiling of circulat
Autor:
Eileen M. O'Reilly, Kenneth H. Yu, Caitlin A. McIntyre, David P. Kelsen, Wungki Park, Jorge S. Reis-Filho, Nima Ghalehsari, Ghassan K. Abou-Alfa, Liying Zhang, Danny N. Khalil, Nadeem Riaz, Xin Pei, Sree Bhavani Chalasani, Joanne F. Chou, Jiapeng Chen, Nicolas Lecomte, Vinod P. Balachandran, Nikolaus Schultz, Imane El Dika, M. Capanu, Pier Selenica, James J. Harding, Anna M. Varghese, Timothy A. Chan, Winston Wong, Vladimir Makarov, Michael F. Berger, S.N. Powell, Mark E. Robson, Christine A. Iacobuzio-Donahue, Zoe McKinnell
Publikováno v:
Clin Cancer Res
Purpose: Genomic methods can identify homologous recombination deficiency (HRD). Rigorous evaluation of their outcome association to DNA damage response–targeted therapies like platinum in pancreatic ductal adenocarcinoma (PDAC) is essential in max
Autor:
Ashkon Rahbari, Wungki Park, Victoria M. Villaflor, Lauren Chiec, Bhoomika Sukhadia, Nisha Mohindra, Victor Wang, Garrett M. Frampton, Sangmin Chang, Jeffrey S. Ross, Si Wang, Zachary R. Chalmers, Siraj M. Ali, Jonathan F. Anker, Vaia Florou, Sang Ha Shin, Jeffrey H. Chuang, Pedro Viveiros, Lee Chun Park, Diana Saravia, Gilberto Lopes, Muhammad Mubbashir Sheikh, Young Kwang Chae, Ethan Sokol, Michael Oh
Publikováno v:
Journal of Thoracic Oncology. 14:1807-1817
Introduction Presently, programmed death ligand 1 is the most commonly used biomarker to predict response to immune checkpoint inhibitors (ICIs) in NSCLC. Owing to its several limitations, there is continuous search for more precise and reliable mark
Publikováno v:
Cancer Metastasis Rev
Pancreas ductal adenocarcinoma (PDAC) is the third most common cause of cancer death in the USA. While other cancers with historically poor prognoses have benefited from new immunotherapies and targeted agents, the 5-year survival rate for PDAC patie